Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
INTERCURE logo — NASDAQ: INCR TASE: INCR TSX: INCR.U

INTERCURE

NASDAQ: INCR TASE: INCR TSX: INCR.U

Founded 2008 Israel Israel 21 employees Manufacturing, Pharmaceutical

General Information

Company Name INTERCURE
Founded Year 2008
Location Israel Israel
Employees 21
Industries Manufacturing, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with INTERCURE. To contact INTERCURE, visit intercure.co.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does INTERCURE compare?

A PDF of INTERCURE and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting INTERCURE soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About INTERCURE

InterCure (dba Canndoc) is a leading cannabis company, traded on NASDAQ: INCR, TSX: INCR.U, and TASE: INCR. Established in 2008, the Israel-based company has positioned itself as the fastest growing cannabis company outside of North America. Its subsidiary, Canndoc, is the largest licensed producer in Israel and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. With a high-margin vertically integrated "seed-to-sale" model and market-leading distribution network, InterCure has established itself as a key player in the rapidly expanding global cannabis market, especially outside North America. The company's commitment to quality and international partnerships enhances its competitive edge. For more insights, visit: www.intercure.co.

Business keywords: cannabis industry, pharmaceutical-grade, medical cannabis, international partnerships, GMP certified, vertical integration, market distribution, global market, Israel, NASDAQ, TSX, TASE, InterCure, Canndoc, seed-to-sale model

No funding data available for INTERCURE yet.

INTERCURE Alternatives & Competitors

View All Alternatives
INTERCURE vs
Gro-Vida
Gro-Vida Portugal

Global supplier of medical cannabis to the pharmaceutical industry

20 employees
Health Care, Manufacturing
INTERCURE vs
Canamedics Lab
Canamedics Lab Spain

Understanding the evolution of medicinal cannabis in Europe. Aspiring to be much more than just anot...

9 employees
Manufacturing, Pharmaceutical
INTERCURE vs
Baader Schulz Laboratories Pvt. Ltd.
Baader Schulz Laboratories Pvt. Ltd. India

A WHO-GMP and ISO 9001:2015 certified pharmaceutical manufacturing company based in India.

39 employees
Manufacturing, Pharmaceutical
View all alternatives

FAQ About INTERCURE

NASDAQ: INCR TASE: INCR TSX: INCR.U
INTERCURE was founded in 2008.
INTERCURE is headquartered in Israel.
INTERCURE operates in Manufacturing and Pharmaceutical. Its work centres on cannabis industry, pharmaceutical-grade, medical cannabis and international partnerships.
INTERCURE has approximately 21 employees.
Top alternatives and competitors to INTERCURE include Gro-Vida, Canamedics Lab, Baader Schulz Laboratories Pvt. Ltd., Eaglechem, Pacific Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
INTERCURE and Gro-Vida are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for INTERCURE, https://bouncewatch.com/company/intercure-1, updated 25 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout